U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C42H73NO16
Molecular Weight 848.0261
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERYTHROMYCIN GLUTARATE

SMILES

[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]2[C@H](C)[C@@H](O[C@]3([H])O[C@H](C)C[C@@H]([C@H]3OC(=O)CCCC(O)=O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]2C

InChI

InChIKey=GMDGJSKLFNMCPF-UCYLELOBSA-N
InChI=1S/C42H73NO16/c1-14-28-42(10,52)35(48)23(4)32(47)21(2)19-40(8,51)37(59-39-34(27(43(11)12)18-22(3)54-39)57-30(46)17-15-16-29(44)45)24(5)33(25(6)38(50)56-28)58-31-20-41(9,53-13)36(49)26(7)55-31/h21-28,31,33-37,39,48-49,51-52H,14-20H2,1-13H3,(H,44,45)/t21-,22-,23+,24+,25-,26+,27+,28-,31+,33+,34-,35-,36+,37-,39+,40-,41-,42-/m1/s1

HIDE SMILES / InChI
Molecular Formula C42H73NO16
Molecular Weight 848.0261
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 18 / 18
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68015643

Erythromycin ethylsuccinate (E.E.S.®, ERY-PED®) is an ester of erythromycin base and succinic acid. It is suitable for oral administration. Erythromycin is a macrolide antibiotic, produced by Saccharopolyspora erythraea (formerly Streptomyces erythraeus). It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin does not affect nucleic acid synthesis.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Information about erythromycin ethylsuccinate is unavailable.

Originator

Eli Lilly
237
Curator's Comment: Information about erythromycin ethylsuccinate is unavailable.

Approval Year

1952
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
 14.0 nM [Kd]
Inhibitor
8297
Binding Agent
1064
 14.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8429
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8429
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8429
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8429
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

1972
Curative
Approved
8429
Davercin

Approved Use

For the topical treatment of acne vulgaris
Curative
Approved
8429
Davercin

Approved Use

For the topical treatment of pneumonia
Curative
Approved
8429
Davercin

Approved Use

Indicated for the treatment of bacterial endocarditis
Curative
Approved
8429
Davercin

Approved Use

Unknown
Curative
Approved
8429
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8429
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8429
E.E.S

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8429
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Curative
Approved
8429
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

1965
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.18 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.44 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.62 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
250 mg 4 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.99 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
250 mg 4 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1161.5 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1386.1 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3544.7 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4096.7 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.48 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.31 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 g 1 times / day single, oral
Studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: single
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
healthy, 12 years
n = 1
Health Status: healthy
Age Group: 12 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
Other AEs: Pancreatitis...
Other AEs:
Pancreatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
5.3 g 1 times / day single, oral
Studied dose
Dose: 5.3 g, 1 times / day
Route: oral
Route: single
Dose: 5.3 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
healthy, 15 years
n = 1
Health Status: healthy
Age Group: 15 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
Other AEs: Pancreatitis...
Other AEs:
Pancreatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
n = 35
Health Status: unhealthy
Condition: maxillary sinusitis
Age Group: mean age 30 years
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
n = 41
Health Status: unhealthy
Condition: maxillary sinusitis
Age Group: mean age 30 years
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Disc. AE: Nausea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nausea (14.6%)
Abdominal pain (4.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
n = 120
Health Status: unhealthy
Condition: streptococcal pharyngitis
Age Group: mean age 44 years
Sex: M+F
Population Size: 120
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Disc. AE: Epigastralgia, Nausea...
AEs leading to
discontinuation/dose reduction:
Epigastralgia (grade 2-3, 2.5%)
Nausea (grade 3, 3.3%)
Vomiting (grade 2, 0.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
n = 9
Health Status: unhealthy
Condition: Parkinson's Disease
Population Size: 9
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Other AEs: Akathisia, Diarrhea...
Other AEs:
Akathisia (below serious, 1 patient)
Diarrhea (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
AEs

AEs

AESignificanceDosePopulation
Pancreatitis
5 g 1 times / day single, oral
Studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: single
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
healthy, 12 years
n = 1
Health Status: healthy
Age Group: 12 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
Pancreatitis
5.3 g 1 times / day single, oral
Studied dose
Dose: 5.3 g, 1 times / day
Route: oral
Route: single
Dose: 5.3 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
healthy, 15 years
n = 1
Health Status: healthy
Age Group: 15 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
Vomiting 2.8%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
n = 35
Health Status: unhealthy
Condition: maxillary sinusitis
Age Group: mean age 30 years
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Nausea 14.6%
Disc. AE
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
n = 41
Health Status: unhealthy
Condition: maxillary sinusitis
Age Group: mean age 30 years
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Abdominal pain 4.9%
Disc. AE
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
n = 41
Health Status: unhealthy
Condition: maxillary sinusitis
Age Group: mean age 30 years
Sex: M+F
Population Size: 41
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Vomiting grade 2, 0.8%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
n = 120
Health Status: unhealthy
Condition: streptococcal pharyngitis
Age Group: mean age 44 years
Sex: M+F
Population Size: 120
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Epigastralgia grade 2-3, 2.5%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
n = 120
Health Status: unhealthy
Condition: streptococcal pharyngitis
Age Group: mean age 44 years
Sex: M+F
Population Size: 120
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Nausea grade 3, 3.3%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
n = 120
Health Status: unhealthy
Condition: streptococcal pharyngitis
Age Group: mean age 44 years
Sex: M+F
Population Size: 120
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Akathisia below serious, 1 patient
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
n = 9
Health Status: unhealthy
Condition: Parkinson's Disease
Population Size: 9
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Diarrhea below serious, 1 patient
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
n = 9
Health Status: unhealthy
Condition: Parkinson's Disease
Population Size: 9
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

P-gp
1461

OATP1B1
788

OATP1B3
706
CYP3A
191

OAT2
115
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 likely
CYP3A4
1925
 moderate [IC50 9.9 uM]
yes (co-administration study)
Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin;
Page: 10.0
OATP1B1
803
 yes [IC50 217 uM]
P-gp
1650
 yes [IC50 22.7 uM]
OATP1B3
715
 yes [IC50 34 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OAT2
115
 yes
CYP3A
191
 yes
likely (co-administration study)
Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0126
http://www.3bsc.com/index/pro_info.php?id=19482
AEchem Scientific Corp., USA
AE061269
https://www.aechemsc.com/info_products/AE061269.php
AHH Chemical co.,ltd
API-1112
http://www.ahhchemical.com/product/API-1112.html
Aaron Chemicals
AR0039Z1
http://www.aaronchem.com/114-07-8
Achemtek
0104-008056
http://www.achemtek.com/114-07-8
Acorn PharmaTech
ACN-048190
http://www.acornpharmatech.com/
Acros Organics
AC227330050
https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227330050
Acros Organics
AC227330250
https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227330250
Acros Organics
AC227331000
https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227331000
Acros Organics
AC343880250
https://www.fishersci.com/shop/products/erythromycin-eur-ph-acros-organics-1/AC343880250
Acros Organics
AC343880050
https://www.fishersci.com/shop/products/erythromycin-eur-ph-acros-organics/AC343880050
Alfa Chemistry
AP114078
https://reagents.alfa-chemistry.com/product/erythromycin-cas-114-07-8-1997.html
Alfa Chemistry
AP114078-B
https://reagents.alfa-chemistry.com/product/erythromycin-cas-114-07-8-1999.html
Alfa Chemistry
AP114078-A
https://reagents.alfa-chemistry.com/product/erythromycin-standard-solution-cas-114-07-8-1998.html
Alfa Chemistry
114-07-8
https://www.alfa-chemistry.com/erythromycin-cas-114-07-8-item-289674.htm
ApexBio Technology
B1939
http://www.apexbt.com/erythromycin.html
Aurora Fine Chemicals LLC
A13.139.732
http://online.aurorafinechemicals.com/info?ID=A13.139.732
Avantor Inc
97061-220
https://us.vwr.com/store/catalog/product.jsp?catalog_number=97061-220
Avantor Inc
200006-440
https://us.vwr.com/store/product/18600820/erythromycin
BLD Pharm
BD17733
http://www.bldpharm.com/products/114-07-8.html
BioCrick
BCC4778
http://www.biocrick.com/Erythromycin-BCC4778.html
BioSynth
E-3250
https://www.biosynth.com/products/biochemistry/culture-media-additives/products/E-3250.html
Boerchem
BC205124
http://www.boerchem.com/?product_34527.html
CSNpharm
CSN12503
https://www.csnpharm.com/products/erythromycin.html
Chem Scene
CS-2168
http://www.chemscene.com/114-07-8.html
ChemMol
30102455
http://www.chemmol.com/chemmol/30102455.html
ChemMol
30102582
http://www.chemmol.com/chemmol/30102582.html
Chemchart
cc-erythromycin
http://chemchart.com/erythromycin-detail.html
Chemspace
CSSB00000053730
https://chem-space.com/CSSB00000053730
DC Chemicals
DC7409
http://www.dcchemicals.com/product_show-E_Mycin.html
Glentham Life Sciences
GA1145
http://www.glentham.com/products/product/GA1145/
Hairui
HR130758
http://www.hairuichem.com/en/product/114-07-8.html
LGC Standards
DRE-A13203490AL-100
https://www.lgcstandards.com/US/en/p/DRE-A13203490AL-100
LGC Standards
DRE-C13203490
https://www.lgcstandards.com/US/en/p/DRE-C13203490
Lab Network
LN00237041
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00237041
MedChem Express
HY-B0220
https://www.medchemexpress.com/Erythromycin.html
MuseChem
A000680
https://www.musechem.com/product/A000680.html
MuseChem
R007004
https://www.musechem.com/product/R007004.html
OChem
657
http://www.ocheminc.com/index.php?act=psearch&pid=114E078
Oakwood
94643
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=79817&ExtHyperLink=1
Parchem
16967
http://www.parchem.com/chemical-supplier-distributor/Erythromycin-006967.aspx
Parchem
10930
http://www.parchem.com/chemical-supplier-distributor/Erythromycines-000930.aspx
Shanghai Tauto Biotech Co., Ltd
E-0288
http://www.tautobiotech.com/BRM/eProductShow.asp?ArticleID=370
Sigma-Aldrich
45674_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/45674?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
BP794_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/bp794?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
E0774_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/e0774?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
45703_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/45703?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1242000_USP
https://www.sigmaaldrich.com/catalog/product/usp/1242000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S527402
http://www.smolecule.com/products/s527402
TCI (Tokyo Chemical Industry)
E0751
http://www.tcichemicals.com/eshop/en/us/commodity/E0751/index.html
THE BioTek
bt-267660
https://www.thebiotek.com/product/inhibitors/bt-267660
VladaChem
VL272699-25G
https://www.vladachem.com/product.php?products=114-07-8
Yuhao Chemical
HL1432
http://www.chemyuhao.com/114-07-8.html
abcr GmbH
AB251852
http://www.abcr.com/shop/en/AB251852
eNovation Chemicals
D565961
https://enovationchem.com/ProductDetails.asp?ProductID=D565961
eNovation Chemicals
D488558
https://www.enovationchem.com/ProductDetails.asp?ProductID=D488558
eNovation Chemicals
D916215
https://www.enovationchem.com/ProductDetails.asp?ProductID=D916215
iChemical
EBD28902
http://www.ichemical.com/products/114-07-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule
MCULE-4566208867
https://mcule.com/MCULE-4566208867/
PubMed

PubMed

TitleDatePubMed
A C-13 relaxation study on erythromycin A cyclic 11,12-carbonate.
1978 May
Comparison of the mechanism of action of cyclic 11,12-erythromycin A carbonate and erythromycin A.
1980
The in-vitro activity of two new quinolones: rufloxacin and MF 961.
1992 Jun
[Bacteriostatic activity and killing curves of eight antibiotics against seven strains of penicillin G-resistant pneumococci].
1992 May
Bioavailability and stability of erythromycin delayed release tablets.
2001 Dec
Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.
2001 Dec
Early and delayed effects of carboplatin on the blood system.
2001 Nov
[Orotic acid as a metabolic agent].
2002
CD34+ stem cells in chronic myeloproliferative disorders.
2002 Apr
Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells.
2002 Apr 15
Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
2002 Aug
Stereodivergent approach to beta-hydroxy alpha-amino acids from C(2)-symmetrical alk-2-yne-1,4-diols.
2002 Dec 12
Ene reaction of singlet oxygen, triazolinedione, and nitrosoarene with chiral deuterium-labeled allylic alcohols: the interdependence of diastereoselectivity and regioselectivity discloses mechanistic insights into the hydroxy-group directivity.
2002 Dec 4
L-erythrulose production by oxidative fermentation is catalyzed by PQQ-containing membrane-bound dehydrogenase.
2002 Feb
Stereoselective binding of 2-(4-biphenylyl)-3-substituted-3-hydroxypropionic acids on an immobilised human serum albumin chiral stationary phase.
2002 Feb 25
[Hormone level and metabolism of xenobiotics in rats with various phenotype of resistance to hypoxia].
2002 Jan-Feb
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
2002 Jul
Dynamics of CD34+ progenitor cells following allogeneic bone marrow transplantation in Ph1+CML--an immunohistochemical study on 113 patients with sequential trephine biopsies.
2002 Jun
Erythro- and threo-2-hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: ligands for A1 adenosine receptors and adenosine deaminase.
2002 Mar
[Legionellosis in HIV-1 infected patients. 4 case reports].
2002 Mar 2
A density-functional study of the mechanism for the diastereoselective epoxidation of chiral allylic alcohols by the titanium peroxy complexes.
2002 Mar 8
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
2002 Oct
Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris.
2002 Sep
QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin.
2002 Sep-Oct
Mixed chimerism of erythro- and megakaryopoiesis following allogeneic bone marrow transplantation.
2003
Synthesis of (+)-aptosimon, a 4-oxofurofuran lignan, by erythro selective aldol condensation and stereoconvergent cyclization as the key reactions.
2003 Apr
[Postoperative ileus: part II (Clinical therapy)].
2003 Apr
Molecular modeling of syringyl and p-hydroxyphenyl beta-O-4 dimers. Comparative study of the computed and experimental conformational properties of lignin beta-O-4 model compounds.
2003 Jan 1
Effect of erythromycin on contractile response of uterine smooth muscle strips in non-pregnant rats.
2003 Jan-Feb
Guaiacylglycerol-7'-O-methyl 8'-vanillic acid ether and related compounds from Boreava orientalis.
2003 Jan-Feb
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face.
2003 Jan-Feb
Stereoselective biosynthesis of chloroarylpropane diols by the basidiomycete Bjerkandera adusta.
2003 Jul
Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce antagonists with increased affinity.
2003 Jun 5
A highly chemoselective, diastereoselective, and regioselective epoxidation of chiral allylic alcohols with hydrogen peroxide, catalyzed by sandwich-type polyoxometalates: enhancement of reactivity and control of selectivity by the hydroxy group through metal-alcoholate bonding.
2003 Mar 7
Systematic synthesis of Bis-THF ring cores in annonaceous acetogenins.
2003 May 1
Straightforward synthesis of sphinganines via a serine-derived Weinreb amide.
2004 Apr 30
Bitterness evaluation of medicines for pediatric use by a taste sensor.
2004 Aug
Delayed Gastric Emptying in Functional Dyspepsia.
2004 Aug
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
2004 Dec
Local mechanisms underlying the regulatory effect of Kropanol on hemopoiesis during paradoxical sleep deprivation.
2004 Feb
Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis.
2004 Feb
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.
2004 Feb 23
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
2004 Jul
[Usefulness of oral exfoliative cytology for the diagnosis of oral squamous dysplasia and carcinoma].
2004 Mar
Effect of mixing method on the mixing degree during the preparation of triturations.
2004 Mar
Conformational study of a guaiacyl beta-O-4 lignin model compound by NMR. Examination of intramolecular hydrogen bonding interactions and conformational flexibility in solution.
2004 Mar
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats.
2004 Sep
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.
2005
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
[Biological effects of a natural alkyl-diacylglyceride preparation in rats with experimental cardioangiopathy].
2005 Mar-Apr
Patents

Patents

03963579
26
06794372
28
EP0119431 A1
26
JP2000229993A
26
JP2000516450A
29
JP2001521945A
47
JP2002121197A
26
JP2002241392A
26
JP2002511777A
414
JP2002520071A
27
JP2002521468A
37
JP2004323414A
26
JP2006137765A
26
JP2006514917A
60
JP2007505906A
51
JP2009137975A
26
JP2009513190A
32
JP2011508747A
61
JP2011526302A
67
JPH06189748A
26
JPH06199887A
26
JPH07247299A
26
JPH07278177A
26
JPH1072457A
26
JPH11322777A
26
JPS05785319A
26
JPS56125382A
26
JPS56147798A
26
JPS58159500A
26
JPS61291516A
32
JPS62115299A
26
JPS62294623A
35
JPS6287599A
26
JPS6423A
26
JPS6466122A
26
US20140128583
26
US2653899
26
US4219641
26
US5118799
26

Sample Use Guides

In Vivo Use Guide
Initial dose - 30 mg/kg, then 15 mg/kg every 12 hours.
Route of Administration: Other
In Vitro Use Guide
At the concentration which stops polylysine synthesis by more than 80% (about 0.5 nM/100 pM of 70S ribosomes), the Erythromycin cyclocarbonate inhibited but slightly binding of phage f2 RNA to ribosomes.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:46:23 GMT 2023
Edited
by admin
on Fri Dec 15 15:46:23 GMT 2023
Record UNII
L26Z5V0FQX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERYTHROMYCIN GLUTARATE
Common Name English
ERYTHROMYCIN 2'-GLUTARATE HEMIESTER
Common Name English
ERYTHROMYCIN, 2'-(HYDROGEN PENTANEDIOATE)
Common Name English
Code System Code Type Description
FDA UNII
L26Z5V0FQX
Created by admin on Fri Dec 15 15:46:23 GMT 2023 , Edited by admin on Fri Dec 15 15:46:23 GMT 2023
PRIMARY
CAS
53904-54-4
Created by admin on Fri Dec 15 15:46:23 GMT 2023 , Edited by admin on Fri Dec 15 15:46:23 GMT 2023
PRIMARY
PUBCHEM
72941564
Created by admin on Fri Dec 15 15:46:23 GMT 2023 , Edited by admin on Fri Dec 15 15:46:23 GMT 2023
PRIMARY
Related Record Type Details
Structure of Erythromycin
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966